Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: A systematic review and meta-analysis

Hematology

Volumn 20, Issue 1, 2015, Pages 1-10

  Łopuch, Sylwia ^a   Kawalec, Paweł ^a   Wiśniewska, Natalia ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Relapsed refractory multiple myeloma; Systematic review and meta analysis; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BORTEZOMIB; DEXAMETHASONE; POMALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADVERSE OUTCOME; ARTICLE; CLINICAL TRIAL (TOPIC); COMORBIDITY; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; NEOPLASM RECURRENCE, LOCAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921732409     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845414Y.0000000159     Document Type: Article

References (53)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127:2893-917.
2. GLOBOCAN 2008 v1.2. [Internet]. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer, 2010 [cited 2013 Sep. 03]. Available from: http://globocan.iarc.fr. Globocan/.
3. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011;8:479-91.
4. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86: 57-65.
5. Kyle RA, Rajkumar SV. Plasma cell disorders. In: Goldman L, Ausiello DA editors. Cecil textbook of medicine. 22nd ed. Philadelphia: WB Saunders; 2004. p. 1184-95.
6. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-73.
7. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867-74.
8. Kyle RA, Gertz MA,Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
9. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc. 2010;85:225-30.
10. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-700.
11. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Practice Res Clin Haematol. 2007;20:625-35.
12. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2011;26:149-57.
13. European Medicine Agency [Internet]. 2013 [cited 2013 Sep 3]. Available from: http://www.ema.europa.eu/.
14. US Food and Drug Administration [Internet]. 2013 August 21 [cited 2013 Sep 3]. Available from: http://www.fda.gov/.
15. Reske T, Fulciniti M, Munshi NC. Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol. 2010;27:S7-13.
16. Quach H, Titchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs in multiple myeloma. Leukemia 2010;24:22-32.
17. Laif T, Chauhan N, Khan R, Moran A, Usmani SZ. Thalidomide and its analogues in the treatment of multiple myeloma. Exp Hemat Oncol. 2012;1:27.
18. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide, and pomalidomide in multiple myeloma. Leuk Lymphoma 2013;54:683-7.
19. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst. 2011;103:1-11.
20. Wang H. Comparative mechanism of action of proteasome inhibitors. Oncology [online] 2011;25 (November 7) [cited 2011 Nov 11]. Available from: http://www.cancernetwork.com/ articles/comparative-mechanisms-action-proteasomeinhibitorsviatheINTERNET.
21. San Miguel JF, Mateos MV, Ocio E, Garcia-Sanz R. Multiple myeloma: treatment evolution. Hematology 2012;17:S3-7.
22. Kyle RA. Targeted therapy of multiple myeloma. Hematology 2012;17:S125-8.
23. National Comprehensive Cancer Network [Internet]. NCCN Clinical Practice Guidelines in Oncology. Multiple myeloma. Version 1.2012. Fort Washington, PA: National Comprehensive Cancer Network, 2012 [cited 2013 Sep 3]; Available from: http://www.nccn.org/professionals/physi cian_gls/f_guidelines.asp#site.
24. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with analogous stem cell transplantation. Leukemia 2009;23:1716-30.
25. Harrousseau JL, Dreyling M. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:155-7.
26. Chiou TJ,Wang TH, Chao TY, Lin SF, Tang JL, Chen TY, et al. Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. Cancer Investig. 2007;25:140-7.
27. Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haemathol. 2011; 154:525-39.
28. Higgins JP, Green S (eds.). Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration and John Wiley & Sons Ltd; 2008.
29. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6:e1000097.
30. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
31. ClinicalTrials.gov [Internet]. MTD, safety, and efficacy of pomalidomide (CC-4047) alone or with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (NCT00833833). 2013 September 02 [cited 2013 Sep 3]. Available from: http://www.clinicaltrials.gov/show/NCT00833833/.
32. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892-901.
33. White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a randomised phase II of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 2012;119:339-47.
34. Goodin S. Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions. Am J Helath-Syst Pharm. 2007;64:S15-24.
35. Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y, et al. Tumor angiogenesis in the bone morrow of multiple myeloma patients and its alternation by thalidomide treatment. Pathol Int. 2004;54:285-94.
36. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Dis Tod. 2007;12:34-42.
37. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26:3777-84.
38. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verril M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337.
39. Zonder JA. Thrombotic complications of myeloma therapy. Hematology 2006;5/6:348-55.
40. von Lilienfeld-Total M, Hahn-Ast C, Furkert K, Hoffmann F, Naumann R, Bargou R, Cook G, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2008;8:247-52.
41. Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymph Myel Leuk. 2011;11:228-36.
42. Prince HM, Adena M, Smith DK, Hertel J. Efficacy of singleagent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic review. Eur J Haemathol. 2007;79:93-99.
43. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Haessler J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 2012;26:149-57.
44. Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, et al. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed refractory multiple myeloma. Br J Haematol. 2009;147:531-4.
45. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008;112:4445-51.
46. Mariz JM, Esteves VG. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. Curr Opin Oncol. 2012;24:S3-12.
47. Yang B, Yu R, Chi X, Lu X. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS ONE 2013;8:e64354.
48. Redic K. Carfilzomib: a novel agent for multiple myeloma. J Pharm Pharmacol. 2013;65:1095-106.
49. Zhu YX, Braggio E, Shi C-X, Bruins LA, Schmidt JE, VanWier S, et al. Cereblon expression is required for antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118: 4774-9.
50. Broyl A, Kuiper R, van Duin M, van der Holt B, el Jaraari L, Bertsch U, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013; 121:624-7.
51. Munishi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004; 103:1799-806.
52. Bagratuni T, Wu P, Gonzalez de Castro D, Davenport EL, Dickens NJ, Walker BA, et al. XBP1 levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood 2010;116: 250-3.
53. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013;24:289-94.